NASDAQ$SIBN

SI-BONE Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

SI-BONE, Inc. reported strong financial results for the first quarter of 2025, achieving significant worldwide revenue growth and positive adjusted EBITDA.

SI-BONE, Inc. announced a strong start to 2025, with worldwide revenue increasing by 24.9% to $47.3 million and U.S. revenue growing by 26.6% to $44.8 million. The company achieved positive adjusted EBITDA of $0.5 million, a significant improvement from a loss in the prior year, and reduced net cash usage by 31.7%.

  • Worldwide revenue increased by 24.9% to $47.3 million.
  • U.S. revenue grew by 26.6% to $44.8 million, driven by strong procedure demand and new product rollouts.
  • Gross margin improved by 80 basis points to 79.7%.
  • Adjusted EBITDA turned positive at $0.5 million, an improvement from a $4.0 million loss in the prior year.

Headline financials

Total Revenue

$47.3M

Previous: $37.9M+24.9%
EPS (adj)

-$0.15

Previous: -$0.27+44.4%
Gross margin

79.7%

Previous: 78.9%+1.0%
Adjusted EBITDA

$500K

Previous: -$4M+112.5%
Active U.S. physicians

1.4K

No prior period
Capital Expenditures

-$2.07M

Previous: -$2.08M+0.5%
Net Income

-$6.54M

Previous: -$10.9M+40.0%
Operating Income

-$7.48M

Previous: -$12M+37.9%
Gross Profit

$37.7M

Previous: $29.9M+26.2%

Revenue & EPS history

SI-BONE · Revenue · Quarterly

$47.3M

Q1 2025+24.9%vs Q1 2024
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

SI-BONE updated its fiscal year 2025 guidance, increasing the worldwide revenue range and maintaining expectations for positive adjusted EBITDA.

Tailwinds

  • Worldwide revenue guidance increased to $193.5 million to $197.5 million, implying 16% to 18% year-over-year growth.
  • Full year 2025 gross margin estimated at 78%.
  • No material impact to gross margins expected from recently announced tariffs.
  • Anticipates positive adjusted EBITDA for the full year 2025.
  • Operating expenses expected to grow at approximately 10% at the mid-point of the revenue guidance.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-1.8%

Avg return

Earnings day

-1.3%

Avg return

5 days after

-0.8%

Avg return

30 days after

40%

12 / 30 earnings

Positive

+16.2%

Q4 2022

Best reaction

-23.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.3%+15.3%
Q4 2025-1.0%-0.6%-17.8%
Q3 2025+16.1%+11.1%+20.0%
Q1 2025+15.6%+29.8%+33.8%
Q4 2024+5.6%+3.7%-19.9%
Q3 2024-17.5%-18.8%-14.5%
Q2 2024-3.6%-5.2%+10.2%
Q1 2024+10.4%+8.0%-1.1%
Q4 2023-12.4%-15.7%-22.0%
Q3 2023-4.7%-12.4%-0.9%
Q2 2023-12.5%-9.6%-7.1%
Q1 2023+9.6%-0.3%+13.9%
Q4 2022+16.2%+19.5%+14.0%
Q3 2022-23.1%-16.4%-26.5%
Q2 2022-6.4%+0.1%+3.5%
Q1 2022-23.7%-27.6%-12.2%
Q4 2021+2.4%+3.2%+3.2%
Q3 2021-7.8%-10.9%-13.6%
Q2 2021-15.1%-18.9%-18.3%
Q1 2021-7.0%-7.5%-17.2%
Q4 2020+4.0%+6.6%+8.3%
Q3 2020+3.2%+0.5%+10.7%
Q2 2020+13.6%+17.7%+31.7%
Q1 2020+9.0%+11.9%+16.3%
Q4 2019-11.9%-21.7%-28.9%
Q3 2019-4.4%-4.5%-0.6%
Q2 2019+6.8%+10.7%+11.3%
Q1 2019-3.9%-8.1%-1.5%
Q4 2018-4.6%-3.6%-9.4%
Q3 2018-3.0%+4.8%+10.5%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q1 2016
Q1 2015
Q4 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro